Lights and Shadows of Clozapine on the Immune System in Schizophrenia: a Narrative Literature Review

Overview

Journal Metab Brain Dis

Publisher Springer

Specialties Endocrinology
Neurology

Date 2025 Feb 15

PMID 39954151

Authors

Jian Liu

Weimin Zhao

Yitong Wang

Affiliations

Soon will be listed here.

Abstract

Schizophrenia is a chronic mental disorder and one of the main causes of disability in the world. Approximately 1% of the general population suffers from this disorder, and almost 30% of cases are unresponsive to antipsychotic therapies. Clozapine is a Food and Drug Administration (FDA)-approved antipsychotic drug for treatment-resistant schizophrenia (TRS). Clozapine is also approved for the prevention of suicide associated with schizophrenia. However, clozapine is not the preferred first-line medication because of its potential AEs, including agranulocytosis, metabolic syndromes, and myocarditis. Clozapine prescription requires weekly absolute neutrophil count (ANC) monitoring for the first six months, followed by biweekly monitoring until the patient has finished one year of treatment. Several psychiatric disorders have been reported to be associated with inflammatory biomarkers. Dysregulation of the immune system and the elevation of pro-inflammatory cytokines were also reported to be associated with schizophrenia, highlighting the necessity of further research into the etiology of the disease and the relationship between the immune system and clozapine-responsiveness to support better management of symptoms and potential AEs. In this framework, we searched PubMed using the medical subject headings (MeSH) terms "clozapine", "antipsychotics", "schizophrenia", "treatment-resistant schizophrenia", "immune system", "inflammation", "neuroinflammation", "biomarker", "cytokine", and "chemokine" with the aim of overview the impact of clozapine on the immune system in individuals with treatment-responsive and treatment-resistant schizophrenia.

References

Al-Dujaili A, Mousa R, Al-Hakeim H, Maes M . High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments. Schizophr Bull. 2020; 47(2):530-541. PMC: 7965081. DOI: 10.1093/schbul/sbaa136. View

Assadiasl S, Rajabinejad M, Soleimanifar N, Makiyan F, Azizi E, Rezaiemanesh A . MicroRNAs-mediated regulation pathways in rheumatic diseases. Inflammopharmacology. 2022; 31(1):129-144. DOI: 10.1007/s10787-022-01097-6. View

Boerrigter D, Weickert T, Lenroot R, ODonnell M, Galletly C, Liu D . Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. J Neuroinflammation. 2017; 14(1):188. PMC: 5604300. DOI: 10.1186/s12974-017-0962-y. View

Buchanan R, Breier A, Kirkpatrick B, Ball P, Carpenter Jr W . Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998; 155(6):751-60. DOI: 10.1176/ajp.155.6.751. View

Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B . Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158(4):518-26. DOI: 10.1176/appi.ajp.158.4.518. View

Chen M, Tsai T, Lin Y, Tsai Y, Wang L, Lee M . Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets. Immunol Lett. 2011; 140(1-2):81-91. DOI: 10.1016/j.imlet.2011.06.011. View

Chen M, Tsai T, Wang L, Lin Y, Tsai Y, Lee M . Clozapine inhibits Th1 cell differentiation and causes the suppression of IFN-γ production in peripheral blood mononuclear cells. Immunopharmacol Immunotoxicol. 2012; 34(4):686-94. DOI: 10.3109/08923973.2011.651535. View

Chen M, Wu S, Tsai T, Wang L, Tsai F . Regulation of macrophage immune responses by antipsychotic drugs. Immunopharmacol Immunotoxicol. 2013; 35(5):573-80. DOI: 10.3109/08923973.2013.828744. View

Cotel M, Lenartowicz E, Natesan S, Modo M, Cooper J, Williams S . Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. Eur Neuropsychopharmacol. 2015; 25(11):2098-107. DOI: 10.1016/j.euroneuro.2015.08.004. View

10.

de Witte L, Tomasik J, Schwarz E, Guest P, Rahmoune H, Kahn R . Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res. 2014; 154(1-3):23-9. DOI: 10.1016/j.schres.2014.02.005. View

11.

DellOsso L, Bonelli C, Nardi B, Giovannoni F, Pronesti C, Cremone I . Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug. Brain Sci. 2024; 14(1). PMC: 10813979. DOI: 10.3390/brainsci14010103. View

12.

Dong Y, Zhu M, Li Y, Liu N, Wang X, Yang B . Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome. Schizophrenia (Heidelb). 2024; 10(1):47. PMC: 11021544. DOI: 10.1038/s41537-024-00469-x. View

12.

Dodd S, Maes M, Anderson G, Dean O, Moylan S, Berk M . Putative neuroprotective agents in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 42:135-45. DOI: 10.1016/j.pnpbp.2012.11.007. View

13.

Drexhage R, Knijff E, Padmos R, Heul-Nieuwenhuijzen L, Beumer W, Versnel M . The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2009; 10(1):59-76. DOI: 10.1586/ern.09.144. View

14.

Fang X, Yu L, Wang D, Chen Y, Wang Y, Wu Z . Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy. Front Psychiatry. 2020; 11:602121. PMC: 7723842. DOI: 10.3389/fpsyt.2020.602121. View

15.

Feng D, Li P, Xiao W, Pei Z, Chen P, Hu M . N-methyladenosine profiling reveals that Xuefu Zhuyu decoction upregulates METTL14 and BDNF in a rat model of traumatic brain injury. J Ethnopharmacol. 2023; 317:116823. DOI: 10.1016/j.jep.2023.116823. View

16.

Fernandez-Egea E, Vertes P, Flint S, Turner L, Mustafa S, Hatton A . Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia. PLoS One. 2016; 11(5):e0155631. PMC: 4887013. DOI: 10.1371/journal.pone.0155631. View

17.

Fillman S, Weickert T, Lenroot R, Catts S, Bruggemann J, Catts V . Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume. Mol Psychiatry. 2015; 21(8):1090-8. PMC: 4960447. DOI: 10.1038/mp.2015.90. View

18.

Fond G, Godin O, Boyer L, Berna F, Andrianarisoa M, Coulon N . Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort. Eur Arch Psychiatry Clin Neurosci. 2018; 269(8):985-992. DOI: 10.1007/s00406-018-0908-0. View

19.

Galea I . The blood-brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021; 18(11):2489-2501. PMC: 8481764. DOI: 10.1038/s41423-021-00757-x. View